Compare LDI & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | SENS |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4M | 496.0M |
| IPO Year | 2021 | 2014 |
| Metric | LDI | SENS |
|---|---|---|
| Price | $0.60 | $9.90 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.00 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 6.6M | 617.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $17.58 | $74.15 |
| Revenue Next Year | $13.99 | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $0.61 | $0.41 |
| 52 Week High | $3.80 | $10.48 |
| Indicator | LDI | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 27.81 | 61.88 |
| Support Level | N/A | $8.45 |
| Resistance Level | $1.19 | $10.07 |
| Average True Range (ATR) | 0.06 | 0.45 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 3.53 | 71.52 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.